Invention Grant
- Patent Title: Rapamycin for the treatment of lymphangioleiomyomatosis
-
Application No.: US17446249Application Date: 2021-08-27
-
Publication No.: US11744797B2Publication Date: 2023-09-05
- Inventor: Henri Lichenstein , Jonathan M. Rothberg , Thomas Armer , Lawrence S. Melvin, Jr.
- Applicant: Al Therapeutics, Inc.
- Applicant Address: US CT Guilford
- Assignee: AI Therapeutics, Inc.
- Current Assignee: AI Therapeutics, Inc.
- Current Assignee Address: US CT Guilford
- Agency: DLA Piper LLP (US)
- Main IPC: A61K9/00
- IPC: A61K9/00 ; A61K31/436 ; A61K31/445 ; A61K47/26 ; A61K9/14 ; A61K9/16 ; A61K45/06
Abstract:
The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
Public/Granted literature
- US20220054410A1 RAPAMYCIN FOR THE TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS Public/Granted day:2022-02-24
Information query
